CAL
NAGE

Capital Advisors Ltd’s Niagen Bioscience NAGE Stock Holding History

Capital Advisors Ltd’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
19
– – ﹤0.01% 1619
2026
Q1 		$0 Hold
19
– – ﹤0.01% 1639
2025
Q4 		$0 Hold
19
– – ﹤0.01% 1610
2025
Q3 		$0 Hold
19
– – ﹤0.01% 1583
2025
Q2 		$0 Hold
19
– – ﹤0.01% 1677
2025
Q1 		$0 Hold
19
– – ﹤0.01% 1625
2024
Q4 		$0 Hold
19
– – ﹤0.01% 1619
2024
Q3 		$0 Hold
19
– – ﹤0.01% 1647
2024
Q2 		$0 Hold
19
– – ﹤0.01% 1683
2024
Q1 		$0 Buy
+19
New +$35 ﹤0.01% 1585

Other funds holding NAGE

SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
MGI
Miller Global Investments Dallas, Texas $121M AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
ANBT
American National Bank & Trust Wichita Falls, Texas $1.17B AUM 36.33% 1-Year Est. Return
OCWP
Owl Creek Wealth Partners Denver, Colorado $342M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM

Capital Advisors Ltd's NAGE Position: Q2 2026 in Review

Capital Advisors Ltd held its Niagen Bioscience (NAGE) position steady in Q2 2026 at 19 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1619.

Capital Advisors Ltd first reported a position in NAGE in Q1 2024 and has held it in 10 quarters since. 14 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Capital Advisors Ltd held 19 shares of Niagen Bioscience worth $0 as of Q2 2026.
  • Capital Advisors Ltd left its Niagen Bioscience share count unchanged in Q2 2026.
  • Niagen Bioscience made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1619 holding.
  • Capital Advisors Ltd first reported a position in Niagen Bioscience in Q1 2024 and has held it in 10 quarters since.
  • 14 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.